Commentary on the Effects of Anakinra on Cardiorespiratory Fitness in Heart Failure Stratified by Age in Phase II Clinical Trials

ABSTRACT: Inflammation is increasingly recognized as a key mechanism driving impaired cardiac function and reduced cardiorespiratory fitness in heart failure. Interleukin-1 blockade with anakinra has shown consistent anti-inflammatory effects but inconclusive benefits on functional capacity in prior trials. In a pooled analysis of 73 patients, Hogwood et al reported that anakinra reduced hsCRP and modestly improved peak VO 2 across both younger (<60 years) and older (≥60 years) patients, with no difference in magnitude of benefit between age groups. These findings indicate that the functional response to IL-1 inhibition is preserved across age groups. Although the results are limited by small sample size, heterogeneous treatment duration, and lack of placebo control, they highlight the importance of age-stratified research and provide a rationale for larger randomized studies assessing long-term clinical outcomes.